Kirk Campbell, MD
- ASSOCIATE PROFESSOR | Medicine, Nephrology
Dr. Kirk Campbell is a graduate of the University of Connecticut School of Medicine. He completed a residency in internal medicine at Yale-New Haven Hospital and a clinical and research fellowship in Nephrology at Mount Sinai Hospital. In addition to treating patients with renal disease, Dr. Campbell leads an NIH-funded research program focused on understanding the mechanism of podocyte injury in the progression of proteinuric kidney diseases. He is a Nephcure Foundation Young Investigator Awardee and a recipient of the Carl Gottschalk Research Scholar Grant from the American Society of Nephrology. Dr. Campbell is the Director of the Nephrology Fellowship Program and an Ombudsperson for medical students at the Icahn School of Medicine at Mount Sinai. He has previously served as a Clinical Attending at Yale-New Haven Hospital and on faculty at the University of Miami Miller School of Medicine. Dr. Campbell is a member of the Medical Advisory Board of the National Kidney Foundation Serving Greater New York.
Multi-Disciplinary Training AreaBiophysics and Systems Pharmacology [BSP]
MD, University of Connecticut
Residency, Internal Medicine, Yale-New Haven Hospital
Fellowship, Nephrology, Mount Sinai Hospital
Kidney podocytes are the target cells for injury in human glomerular disease, a significant cause of end stage kidney failure. Primary and secondary pathogenic processes affecting podocytes account for 90% of end-stage kidney disease at a cost of 20 billion dollars per year in the US. A reduction in podocyte number (podocytopenia) directly correlates with the progression of several proteinuric kidney diseases including focal segmental glomerulosclerosis (FSGS), IgA nephropathy and diabetic nephropathy. Despite significant advances in the characterization of the molecular architecture of podocytes, the mechanisms underlying their survival, injury and loss remain poorly understood. Validated therapeutic targets are scarce and there are currently no podocyte-specific drugs commercially available. The overall goal of our research program is to enhance the pipeline of putative therapeutic targets available to tackle human glomerular disease by elucidating the details and functional significance of key signaling pathways that regulate podocyte injury and survival. We utilize cell-based assays and rodent models to identify and characterize key mediators of glomerular disease progression.
- Efficacy and Safety of Sparsentan (RE-021) A Dual Endothelin Receptor and Angiotensin Receptor Blocker In Patients with Focal Segmental Glomerulosclerosis (FSGS): A Randomized Double-Blind Active-Control Dose-Escalation Study
The purpose of this study is to collect information about the possible effects of Sparsentan to treat the urine protein loss in patients with FSGS (Focal Segmental Glomerulosclerosis) as well as other positive and negative effects of the treatment. In this study the sponsor Re...
- A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Proliferative Lupus Nephritis
The purpose of this study is to see if anifrolumab may have an effect in treating lupus nephritis, to see how well it is tolerated, and to measure levels of anifrolumab in the blood. Subjects may qualify to take part in this research study because they have lupus nephrit...
Asanuma K, Campbell KN, Kim K, Faul C, Mundel P. Nuclear relocation of the nephrin and CD2AP-binding protein dendrin promotes apoptosis of podocytes. Proceedings of the National Academy of Sciences of the United States of America 2007 Jun; 104(24).
Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, Chang JM, Choi HY, Campbell KN, Kim K, Reiser J, Mundel P. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nature medicine 2008 Sep; 14(9).
Sieber J, Lindenmeyer MT, Kampe K, Campbell KN, Cohen CD, Hopfer H, Mundel P, Jehle AW. Regulation of podocyte survival and endoplasmic reticulum stress by fatty acids. American journal of physiology. Renal physiology 2010 Oct; 299(4).
Campbell KN, Raij L, Mundel P. Role of angiotensin II in the development of nephropathy and podocytopathy of diabetes. Current diabetes reviews 2011 Jan; 7(1).
Campbell KN, Wong JS, Gupta R, Asanuma K, Sudol M, He JC, Mundel P. Yes-associated protein (YAP) promotes cell survival by inhibiting proapoptotic dendrin signaling. The Journal of biological chemistry 2013 Jun; 288(24).
Yu CC, Fornoni A, Weins A, Hakroush S, Maiguel D, Sageshima J, Chen L, Ciancio G, Faridi MH, Behr D, Campbell KN, Chang JM, Chen HC, Oh J, Faul C, Arnaout MA, Fiorina P, Gupta V, Greka A, Burke GW, Mundel P. Abatacept in B7-1-positive proteinuric kidney disease. The New England journal of medicine 2013 Dec; 369(25).
Potla U, Ni J, Vadaparampil J, Yang G, Leventhal JS, Campbell KN, Chuang PY, Morozov A, He JC, D'Agati VD, Klotman PE, Kaufman L. Podocyte-specific RAP1GAP expression contributes to focal segmental glomerulosclerosis-associated glomerular injury. The Journal of clinical investigation 2014 Apr; 124(4).
Campbell KN, He JC. Can biomarkers of disease activity guide treatment in FSGS?. Clinical journal of the American Society of Nephrology : CJASN 2014 Sep; 9(9).
Yacoub R, Campbell KN. Inhibition of RAS in diabetic nephropathy. International journal of nephrology and renovascular disease 2015; 8.
Schwartzman M, Reginensi A, Wong JS, Basgen JM, Meliambro K, Nicholas SB, D'Agati V, McNeill H, Campbell KN. Podocyte-Specific Deletion of Yes-Associated Protein Causes FSGS and Progressive Renal Failure. Journal of the American Society of Nephrology : JASN 2015 May;.